The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma
Open accessAbstract
Significance: Despite initial responsiveness to chemotherapy, the overwhelming majority of advanced ovarian cancer patients relapse with resistant disease. Thus, developing more effective strategies for ovarian cancer treatment is a high clinical priority. Here, we report that targeting angiotensin signaling with losartan, an angiotensin receptor blocker, can reduce extracellular matrix in ovarian tumors and the associated physical barriers that normally hinder drug delivery and efficacy. These changes in the tumor microenvironment lead to improved response to chemotherapy, and, importantly, decrease ascites—a major burden for ovarian cancer patients. These preclinical findings are in concert with our retrospective analysis showing improved survival in patients receiving angiotensin system inhibitors concurrently with standard treatment for ovarian cancer and should be tested in a clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A., & Olson, E. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805038105 · Cited by 1,844
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“The reduction in perfusion leads to (i) reduced delivery of drugs to tumors, which compromises treatment efficacy (13), and (ii) increased tumor hypoxia, which promotes aggressive phenotypes, immunosuppression, and resistance to chemotherapy, radiation, and immunotherapy, which require oxygen to be effective (14).”
BackgroundSelf-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationRole of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationThe Role of Mechanical Forces in Tumor Growth and Therapy
Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105259 · Cited by 1,044 · cited 1×
“As tumor blood vessels are structurally abnormal, these vessels are easily collapsible under this high compressive force, resulting in reduced blood flow throughout the tumor mass (8, 9, 11, 12).”
BackgroundSelf-citationChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943
Self-citationFibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Self-citationDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · cited 2×
“As a consequence solid stress was reduced, vessel compression was alleviated, and vascular perfusion was enhanced, resulting in reduced tumor hypoxia and improved delivery and efficacy of both lowmolecular-weight drugs and nanomedicine (9, 20).”
BackgroundSelf-citationColeman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
TGF-β/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29
Qin, W., Chung, A. C. K., Huang, X. R., Meng, X.-M., Hui, D. S. C., Yu, C.-M., Sung, J. J. Y., & Lan, H. Y. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121308 · Cited by 566
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Self-citationMicroRNA‐29, a key regulator of collagen expression in systemic sclerosis
Maurer, B., Stanczyk, J., Jüngel, A., Akhmetshina, A., Trenkmann, M., Brock, M., Kowal‐Bielecka, O., Gay, R. E., Michel, B. A., Distler, J. H. W., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27443 · Cited by 539
miR-29 Is a Major Regulator of Genes Associated with Pulmonary Fibrosis
Cushing, L., Kuang, P. P., Qian, J., Shao, F., Wu, J., Little, F., Thannickal, V. J., Cardoso, W. V., & Lü, J. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0323oc · Cited by 502
Suppression of microRNA-29 Expression by TGF-β1 Promotes Collagen Expression and Renal Fibrosis
Wang, B., Komers, R., Carew, R., Winbanks, C. E., Xu, B., Herman-Edelstein, M., Koh, P., Thomas, M., Jandeleit-Dahm, K., Gregorevic, P., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011010055 · Cited by 498
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482
Solid stress and elastic energy as measures of tumour mechanopathology
Nia, H. T., Liu, H., Seano, G., Datta, M., Jones, D., Rahbari, N., Incio, J., Chauhan, V. P., Jung, K., Martin, J. D., et al. (2016) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0004 · Cited by 449
Self-citationTargeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Self-citationLiu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
Self-citationAghajanian, C., Goff, B., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 320
Michel, M. C., Foster, C., Brunner, H. R., & Liu, L. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007278 · Cited by 301
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311416259 · Cited by 284
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00027-6 · Cited by 271
Self-citationMarkedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites
Zebrowski, B. K., Liu, W., Ramirez, K., Akagi, Y., Mills, G. B., & Ellis, L. M. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0373-0 · Cited by 254
MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma
Hayes, C., & Chayama, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030280 · Cited by 223
Acquired chemotherapy resistance in ovarian cancer
Christie, E. L., & Bowtell, D. D. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx446 · Cited by 220
Cardiac miR‐133a overexpression prevents early cardiac fibrosis in diabetes
Chen, S., Puthanveetil, P., Feng, B., Matkovich, S. J., Dorn, G. W., & Chakrabarti, S. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12218 · Cited by 202
Castoldi, G., di Gioia, C. R. T., Bombardi, C., Catalucci, D., Corradi, B., Gualazzi, M. G., Leopizzi, M., Mancini, M., Zerbini, G., Condorelli, G., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22939 · Cited by 202
Harada, K., Sugaya, T., Murakami, K., Yazaki, Y., & Komuro, I. (1999) · Circulation · doi:10.1161/01.cir.100.20.2093 · Cited by 201
Novel TGF-β inhibitors ready for prime time in onco-immunology
de Gramont, A., Faivre, S., & Raymond, E. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1257453 · Cited by 183
MicroRNAs in fibrosis: opportunities and challenges
O’Reilly, S. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0929-x · Cited by 165
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158 · cited 1×
“For patients with ovarian cancer who have a complete or partial response to platinum-based chemotherapy, there are now three poly ADP ribose polymerase (PARP) inhibitors (olaparib, niraparib, and rucaparib) approved for use in the maintenance setting (36, 37).”
BackgroundKaram, A., Ledermann, J. A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B.-H., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx011 · Cited by 153
Transvascular drug delivery in solid tumors
Fan, Y. (1998) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(98)80042-8 · Cited by 132
Roderburg, C., Luedde, M., Cardenas, D. V., Vucur, M., Mollnow, T., Zimmermann, H. W., Koch, A. H., Hellerbrand, C., Weiskirchen, R., Frey, N., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.022 · Cited by 130
Pegylated liposomal doxorubicin in ovarian cancer.
Green, A. E., & Rose, P. G. (2006) · PubMed Central · Cited by 128
Séror, O., Nkontchou, G., Nault, J., Rabahi, Y., Nahon, P., Ganne‐Carrié, N., Grando, V., Zentar, N., Beaugrand, M., Trinchet, J., et al. (2016) · Radiology · doi:10.1148/radiol.2016150743 · Cited by 126
Ino, K., Shibata, K., Kajiyama, H., Yamamoto, E., Nagasaka, T., Nawa, A., Nomura, S., & Kikkawa, F. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602961 · Cited by 125
Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice
Yang, L., Bataller, R. A., Dulyx, J., Coffman, T. M., Ginès, P., Rippe, R. A., & Brenner, D. A. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.02.034 · Cited by 114
Cancer biomarker profiling with microRNAs
Jeffrey, S. S. (2008) · Nature Biotechnology · doi:10.1038/nbt0408-400 · Cited by 113
Quantifying solid stress and elastic energy from excised or in situ tumors
Nia, H. T., Datta, M., Seano, G., Huang, P., Munn, L. L., & Jain, R. K. (2018) · Nature Protocols · doi:10.1038/nprot.2018.020 · Cited by 101
Self-citationMicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring
Schena, F. P., Serino, G., & Sallustio, F. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft223 · Cited by 97
Liu, H., Naxerova, K., Pinter, M., Incio, J., Lee, H., Shigeta, K., Ho, W. W., Crain, J. A., Jacobson, A., Michelakos, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0256 · Cited by 96
Self-citationResolving The Nanoparticles Paradox
Donaldson, K. (2006) · Nanomedicine · doi:10.2217/17435889.1.2.229 · Cited by 95
Hong, S., Lee, H.-J., Kim, S. J., & Hahm, K. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i17.2080 · Cited by 81
Schwarz, R. I. (2015) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2015.07.007 · Cited by 79
Gueorguieva, I., Cleverly, A., Stauber, A. J., Pillay, N. S., Rodon, J. A., Miles, C., Yingling, J. M., & Lahn, M. M. F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12256 · Cited by 78
Liao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2429 · Cited by 75
Self-citationThe poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities
Moore, K. N., Mirza, M. R., & Matulonis, U. A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.01.011 · Cited by 66
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Morgan, R. D., Clamp, A. R., Evans, D. G., Edmondson, R. J., & Jayson, G. C. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3532-9 · Cited by 66
Renin–Angiotensin System Inhibitors to Mitigate Cancer Treatment–Related Adverse Events
Pinter, M., Kwanten, W. J., & Jain, R. K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0236 · Cited by 64
Self-citationEmerging treatment options for management of malignant ascites in patients with ovarian cancer
Tewari, K. S., & Eskander, R. N. (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s29467 · Cited by 41
Pan, J., Zhang, J., Zhang, X., Zhou, X., LU, S., Huang, X., SHAO, J., Lou, G., Yang, D., & Geng, Y. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1935 · Cited by 36
Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer
Beyazıt, F., Ayhan, S., Celik, H. T., & Gungor, T. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3661-x · Cited by 32
Song, L., Zhang, S., Bai, K., Yang, J., Xiong, H., Li, X., Liu, T., & Liu, H. (2013) · Journal of Ovarian Research · doi:10.1186/1757-2215-6-22 · Cited by 18
Lorusso, D., Fontanella, C., Maltese, G., Lepori, S., Tripodi, E., Bogani, G., & Raspagliesi, F. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1325871 · Cited by 11
Cited by
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Self-citationThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13092053 · Cited by 456
Self-citation
Metadata
- Authors
- Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., Mpekris, F., Datta, M., Sun, Y., Wu, L., Gao, X., Yeku, O., del Carmen, M. G., Spriggs, D. R., Jain, R. K., & Xu, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-01-18
- Volume
- 116
- Issue
- 6
- Pages
- 2210-2219
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2909932177
- Cited by
- 259
- References
- 62
- FWCI
- 27.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.